CytomX Therapeutics, Inc.
198 articles with CytomX Therapeutics, Inc.
-
CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
3/22/2023
CytomX Therapeutics, Inc., a leader in the field of conditionally activated, localized biologics, announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets.
-
CytomX Therapeutics to Present at Upcoming March 2023 Investor Conferences
2/28/2023
CytomX Therapeutics, Inc., a leader in the field of conditionally activated, localized biologics, announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in March.
-
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
1/26/2023
CytomX Therapeutics, Inc. today announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas.
-
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
1/17/2023
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 19, 2023 at 2:30 p.m. ET.
-
Moderna and CytomX ink a cancer partnership.
-
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
1/5/2023
Moderna, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody® therapeutic platform.
-
CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
1/5/2023
CytomX Therapeutics, Inc. announced its 2023 company priorities and provided a pipeline update which included anticipated milestones for 2023, recent progress and achievements in its wholly owned and collaboration pipeline, and a data update for the Phase 2, CX-2029 cohort expansion study.
-
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
1/5/2023
CytomX Therapeutics, Inc. and Moderna, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody® therapeutic platform.
-
CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
12/22/2022
CytomX Therapeutics, Inc. announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets.
-
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/20/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. ET.
-
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
12/7/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Phase 2 data for CX-2009, a conditionally activated antibody drug conjugate (ADC) targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8th.
-
Regeneron and CytomX Therapeutics inked a deal valued at up to $2 billion to develop next-generation bispecific immunotherapies for cancer, the companies announced Thursday.
-
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
11/17/2022
Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. today announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform and Regeneron's Veloci-Bi® bispecific antibody development platform.
-
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
11/17/2022
CytomX Therapeutics, Inc. (NASDAQ: CTMX) and Regeneron Pharmaceuticals, Inc today announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX’s Probody® therapeutic platform and Regeneron’s Veloci-Bi® bispecific antibody development platform.
-
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
11/8/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported third quarter 2022 financial results and provided a business update.
-
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
11/7/2022
CytomX Therapeutics, Inc. announced that preclinical data for CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer Annual Meeting in Boston, Massachusetts.
-
CytomX Therapeutics to Present at Upcoming November 2022 Investor Conferences
11/2/2022
CytomX Therapeutics, Inc., a leader in the field of conditionally activated oncology therapeutics, announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in November.
-
CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022
11/1/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of U.S. markets.
-
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
9/12/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that its collaborator, Bristol Myers Squibb, presented updated Phase 1 results with BMS-986249, a Probody® therapeutic version of ipilimumab, the anti-CTLA-4 antibody, at the ESMO Congress 2022 in Paris, France.
-
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
9/7/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the Company presented advances within its conditionally-activated ADC portfolio, including the next generation EpCAM-ADC, CX-2051, at the World ADC conference taking place September 6-9, 2022, in San Diego, CA.